Published in J Virol on March 01, 2005
Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway. PLoS Pathog (2016) 1.41
Vaginal epithelial dendritic cells renew from bone marrow precursors. Proc Natl Acad Sci U S A (2007) 1.21
Herpes simplex virus and the chemokines that mediate the inflammation. Curr Top Microbiol Immunol (2006) 1.20
Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. J Virol (2005) 1.14
Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays (2012) 1.04
Apolipoprotein E alleles can contribute to the pathogenesis of numerous clinical conditions including HSV-1 corneal disease. Exp Eye Res (2006) 0.98
The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol (2005) 0.95
Illumination of murine gammaherpesvirus-68 cycle reveals a sexual transmission route from females to males in laboratory mice. PLoS Pathog (2013) 0.94
Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women. Clin Vaccine Immunol (2010) 0.92
Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol (2011) 0.91
Psychological stress exacerbates primary vaginal herpes simplex virus type 1 (HSV-1) infection by impairing both innate and adaptive immune responses. Brain Behav Immun (2008) 0.87
Accelerated immune senescence and reduced response to vaccination in ovariectomized female rhesus macaques. Age (Dordr) (2010) 0.87
Estradiol improves genital herpes vaccine efficacy in mice. Vaccine (2009) 0.85
Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice. Vaccine (2009) 0.83
Nanoparticle-based drug delivery to the vagina: a review. J Control Release (2014) 0.83
HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine. Viruses (2014) 0.82
A novel pre-clinical murine model to study the life cycle and progression of cervical and anal papillomavirus infections. PLoS One (2015) 0.78
Association of increased prenatal estrogen with risk factors for schizophrenia. Schizophr Bull (2010) 0.77
High Physiological Concentrations of Progesterone Reverse Estradiol-Mediated Changes in Differentiation and Functions of Bone Marrow Derived Dendritic Cells. PLoS One (2016) 0.75
Effects of Female Sex Hormones on Susceptibility to HSV-2 in Vaginal Cells Grown in Air-Liquid Interface. Viruses (2016) 0.75
Sex Drives Dimorphic Immune Responses to Viral Infections. J Immunol (2017) 0.75
Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites. Mucosal Immunol (2017) 0.75
A novel role for IL-17 in enhancing type 1 helper T cell immunity in the female genital tract following mucosal HSV-2 vaccination. J Virol (2017) 0.75
Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med (2002) 6.23
Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med (1996) 5.63
The neutrophil as a cellular source of chemokines. Immunol Rev (2000) 4.09
Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol (2002) 3.38
A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest (1994) 3.00
Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis (1998) 2.96
Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev (2003) 2.06
Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol (2003) 2.04
Hormone therapy: physiological complexity belies therapeutic simplicity. Science (2004) 1.68
Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Virology (1996) 1.56
Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis (2000) 1.52
Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol (2003) 1.46
Effects of reproductive hormones on experimental vaginal candidiasis. Infect Immun (2000) 1.44
Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract. Infect Immun (2000) 1.42
In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa. J Virol (2004) 1.39
Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. J Virol (1999) 1.35
Antigen-presenting cells in the female reproductive tract: influence of the estrous cycle on antigen presentation by uterine epithelial and stromal cells. Endocrinology (1995) 1.32
Role of mucosal immunity in herpes simplex virus infection. J Immunol (1998) 1.29
The interaction of neutrophils with respiratory epithelial cells in viral infection. Respirology (2000) 1.27
Influence of ovarian hormones on urogenital infection. Sex Transm Infect (1998) 1.19
Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS (2004) 1.19
Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. J Virol (2005) 1.14
Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways. J Soc Gynecol Investig (2000) 1.01
Hormonal factors and the laboratory detection of Chlamydia trachomatis in women: implications for screening? Int J STD AIDS (1997) 1.01
The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes (2001) 0.96
Potential for immunotherapy in the treatment of herpesvirus infections. Herpes (2001) 0.91
Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog (2010) 2.57
Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol (2003) 2.04
Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol (2003) 1.83
Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol (2010) 1.76
Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS (2008) 1.55
Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol (2003) 1.46
Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol (2003) 1.37
Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis (2004) 1.36
HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers. PLoS One (2009) 1.35
Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. J Virol (2009) 1.18
Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. J Virol (2005) 1.14
Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med (2002) 1.10
NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection. J Virol (2005) 1.08
Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract. J Reprod Immunol (2010) 1.07
Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine (2004) 1.04
Differential induction of innate anti-viral responses by TLR ligands against Herpes simplex virus, type 2, infection in primary genital epithelium of women. Antiviral Res (2008) 1.02
Susceptibility of human female primary genital epithelial cells to herpes simplex virus, type-2 and the effect of TLR3 ligand and sex hormones on infection. Biol Reprod (2007) 0.99
Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol (2003) 0.98
IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res (2011) 0.97
HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium. J Immunol (2013) 0.96
Mucosal delivery of CpG oligodeoxynucleotides expands functional dendritic cells and macrophages in the vagina. Immunology (2005) 0.94
Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis (2002) 0.94
Development of functional human NK cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge. PLoS One (2009) 0.92
War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem Soc Trans (2011) 0.92
Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner. J Infect Dis (2011) 0.92
Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848). Antiviral Res (2005) 0.90
Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells. J Virol (2012) 0.88
Innate and adaptive immune responses in male and female reproductive tracts in homeostasis and following HIV infection. Cell Mol Immunol (2014) 0.88
Vaccines in the public eye. Nat Med (2005) 0.87
Expression of Toll-like receptors in murine vaginal epithelium is affected by the estrous cycle and stromal cells. J Reprod Immunol (2007) 0.87
HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection. Microb Pathog (2012) 0.87
Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone. Vaccine (2008) 0.86
Antiviral activity of trappin-2 and elafin in vitro and in vivo against genital herpes. J Virol (2013) 0.85
Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses. AIDS Res Hum Retroviruses (2003) 0.84
Estradiol limits viral replication following intravaginal immunization leading to diminished mucosal IgG response and non-sterile protection against genital herpes challenge. Am J Reprod Immunol (2010) 0.83
Proinflammatory cytokines and chemokines - but not interferon-β - produced in response to HSV-2 in primary human genital epithelial cells are associated with viral replication and the presence of the virion host shutoff protein. Am J Reprod Immunol (2013) 0.81
Influence of common mucosal co-factors on HIV infection in the female genital tract. Am J Reprod Immunol (2014) 0.80
Differential responses of murine vaginal and uterine epithelial cells prior to and following herpes simplex virus type 2 (HSV-2) infection. Am J Reprod Immunol (2007) 0.79
Anti-HIV-1 activity of elafin depends on its nuclear localization and altered innate immune activation in female genital epithelial cells. PLoS One (2012) 0.79
Trappin-2/elafin modulate innate immune responses of human endometrial epithelial cells to PolyI:C. PLoS One (2012) 0.79
Milk matters: soluble Toll-like receptor 2 (sTLR2) in breast milk significantly inhibits HIV-1 infection and inflammation. PLoS One (2012) 0.79
Latent TGF-β1 is compartmentalized between blood and seminal plasma of HIV-positive men and its activation in semen is negatively correlated with viral load and immune activation. Am J Reprod Immunol (2014) 0.77
Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. Clin Infect Dis (2013) 0.77
Production of CD8+ T cell nonlytic suppressive factors by CD28, CD38, and HLA-DR subpopulations. AIDS Res Hum Retroviruses (2003) 0.76
Correction: Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway. PLoS Pathog (2016) 0.75
Identification of mutations in proviral long terminal repeats of HIV type 1-infected subjects naive to drug therapy. AIDS Res Hum Retroviruses (2004) 0.75
Continuous antigenic stimulation system (CASS) as a new immunization strategy. Vaccine (2004) 0.75